$51.17
Insights on Azenta Inc
Revenue is down for the last 2 quarters, 172.35M → 154.31M (in $), with an average decrease of 10.5% per quarter
Netprofit is down for the last 2 quarters, 3.37M → -15.72M (in $), with an average decrease of 565.9% per quarter
In the last 1 year, Intuitive Surgical, Inc. has given 39.0% return, outperforming this stock by 23.2%
0.16%
Downside
Day's Volatility :2.41%
Upside
2.25%
29.63%
Downside
52 Weeks Volatility :47.93%
Upside
26.01%
Period | Azenta Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -22.58% | -0.7% | 0.0% |
6 Months | 0.97% | 6.6% | 0.0% |
1 Year | 15.82% | 3.7% | -1.5% |
3 Years | -48.86% | 14.0% | -21.8% |
Market Capitalization | 2.9B |
Book Value | $43.86 |
Earnings Per Share (EPS) | -0.32 |
Wall Street Target Price | 69.6 |
Profit Margin | -2.92% |
Operating Margin TTM | -16.56% |
Return On Assets TTM | -1.47% |
Return On Equity TTM | -0.65% |
Revenue TTM | 641.0M |
Revenue Per Share TTM | 10.29 |
Quarterly Revenue Growth YOY | -13.5% |
Gross Profit TTM | 272.8M |
EBITDA | 15.4M |
Diluted Eps TTM | -0.32 |
Quarterly Earnings Growth YOY | 87.78 |
EPS Estimate Current Year | 0.26 |
EPS Estimate Next Year | 0.53 |
EPS Estimate Current Quarter | -0.03 |
EPS Estimate Next Quarter | 0.04 |
What analysts predicted
Upside of 36.02%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 631.6M | ↓ 8.85% |
Net Income | 116.6M | ↑ 86.19% |
Net Profit Margin | 18.46% | ↑ 9.42% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 781.9M | ↑ 23.8% |
Net Income | 9.9M | ↓ 91.52% |
Net Profit Margin | 1.26% | ↓ 17.2% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 897.3M | ↑ 14.76% |
Net Income | 64.9M | ↑ 555.74% |
Net Profit Margin | 7.23% | ↑ 5.97% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 513.7M | ↓ 42.75% |
Net Income | -28.9M | ↓ 144.51% |
Net Profit Margin | -5.62% | ↓ 12.85% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 555.5M | ↑ 8.14% |
Net Income | -11.3M | ↓ 60.91% |
Net Profit Margin | -2.03% | ↑ 3.59% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 665.1M | ↑ 19.73% |
Net Income | -14.3M | ↑ 26.32% |
Net Profit Margin | -2.14% | ↓ 0.11% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 137.6M | ↑ 3.64% |
Net Income | -5.3M | ↓ 24.31% |
Net Profit Margin | -3.86% | ↑ 1.42% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 178.4M | ↑ 29.66% |
Net Income | -11.2M | ↑ 111.58% |
Net Profit Margin | -6.3% | ↓ 2.44% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 148.4M | ↓ 16.8% |
Net Income | -2.0M | ↓ 82.28% |
Net Profit Margin | -1.34% | ↑ 4.96% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 165.9M | ↑ 11.82% |
Net Income | -1.5M | ↓ 26.17% |
Net Profit Margin | -0.89% | ↑ 0.45% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 172.4M | ↑ 3.86% |
Net Income | 3.4M | ↓ 329.59% |
Net Profit Margin | 1.96% | ↑ 2.85% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 154.3M | ↓ 10.47% |
Net Income | -15.7M | ↓ 565.9% |
Net Profit Margin | -10.19% | ↓ 12.15% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.1B | ↑ 42.96% |
Total Liabilities | 378.2M | ↑ 137.87% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.5B | ↑ 38.42% |
Total Liabilities | 377.8M | ↓ 0.11% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.6B | ↑ 2.77% |
Total Liabilities | 345.5M | ↓ 8.54% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↑ 16.7% |
Total Liabilities | 494.2M | ↑ 43.03% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 3.7B | ↑ 104.24% |
Total Liabilities | 352.7M | ↓ 28.62% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 2.9B | ↓ 22.35% |
Total Liabilities | 351.2M | ↓ 0.43% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 3.7B | ↓ 0.18% |
Total Liabilities | 352.7M | ↑ 19.6% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 3.3B | ↓ 11.4% |
Total Liabilities | 421.0M | ↑ 19.36% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.2B | ↓ 1.29% |
Total Liabilities | 354.6M | ↓ 15.78% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.1B | ↓ 5.55% |
Total Liabilities | 345.9M | ↓ 2.45% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.9B | ↓ 5.98% |
Total Liabilities | 351.2M | ↑ 1.53% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.8B | ↓ 2.13% |
Total Liabilities | 380.7M | ↑ 8.38% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 74.0M | ↓ 23.13% |
Investing Cash Flow | -148.5M | - |
Financing Cash Flow | 170.3M | ↓ 756.93% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 90.9M | ↑ 22.89% |
Investing Cash Flow | 211.3M | ↓ 242.33% |
Financing Cash Flow | -191.2M | ↓ 212.26% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 37.9M | ↓ 58.34% |
Investing Cash Flow | -22.7M | ↓ 110.76% |
Financing Cash Flow | -27.0M | ↓ 85.86% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 149.9M | ↑ 295.76% |
Investing Cash Flow | -146.3M | ↑ 543.52% |
Financing Cash Flow | -25.9M | ↓ 4.13% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -466.0M | ↓ 410.99% |
Investing Cash Flow | 1.5B | ↓ 1101.43% |
Financing Cash Flow | -62.8M | ↑ 142.27% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 17.5M | ↓ 103.75% |
Investing Cash Flow | 431.4M | ↓ 70.57% |
Financing Cash Flow | -844.1M | ↑ 1244.89% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 9.6M | ↓ 102.29% |
Investing Cash Flow | -374.5M | ↓ 1275.13% |
Financing Cash Flow | 1.8M | ↓ 267.88% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -27.0M | ↓ 380.47% |
Investing Cash Flow | 56.4M | ↓ 115.05% |
Financing Cash Flow | -504.7M | ↓ 28924.67% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -12.2M | ↓ 55.03% |
Investing Cash Flow | 58.2M | ↑ 3.23% |
Financing Cash Flow | -416.0K | ↓ 99.92% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 16.7M | ↓ 237.84% |
Investing Cash Flow | 214.4M | ↑ 268.49% |
Financing Cash Flow | -172.1M | ↑ 41266.59% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 39.9M | ↑ 138.31% |
Investing Cash Flow | 102.5M | ↓ 52.19% |
Financing Cash Flow | -166.9M | ↓ 3.04% |
Sell
Neutral
Buy
Azenta Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Azenta Inc | -12.05% | 0.97% | 15.82% | -48.86% | -48.86% |
Intuitive Surgical, Inc. | -4.7% | 35.81% | 38.95% | 38.38% | 112.57% |
Resmed Inc. | -8.97% | 22.05% | -22.01% | -15.48% | 75.2% |
Becton, Dickinson And Company | -2.32% | -10.48% | -8.43% | -10.33% | 1.9% |
West Pharmaceutical Services Inc | -4.64% | 0.62% | 4.23% | 19.12% | 238.38% |
Alcon Ag | -6.1% | 7.94% | 11.1% | 7.08% | 42.78% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Azenta Inc | 1.57 | NA | NA | 0.26 | -0.01 | -0.01 | NA | 43.86 |
Intuitive Surgical, Inc. | 75.26 | 75.26 | 7.13 | 6.25 | 0.15 | 0.08 | NA | 37.77 |
Resmed Inc. | 30.61 | 30.61 | 1.75 | 7.41 | 0.22 | 0.11 | 0.01 | 30.47 |
Becton, Dickinson And Company | 52.86 | 52.86 | 1.34 | 12.95 | 0.05 | 0.03 | 0.02 | 87.68 |
West Pharmaceutical Services Inc | 48.1 | 48.1 | 6.72 | 7.62 | 0.21 | 0.12 | 0.0 | 39.2 |
Alcon Ag | 40.62 | 40.62 | 4.59 | 3.06 | 0.05 | 0.02 | 0.0 | 41.81 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Azenta Inc | Buy | $2.9B | -48.86% | 1.57 | -2.92% |
Intuitive Surgical, Inc. | Buy | $134.2B | 112.57% | 75.26 | 25.24% |
Resmed Inc. | Buy | $27.2B | 75.2% | 30.61 | 19.77% |
Becton, Dickinson And Company | Buy | $67.8B | 1.9% | 52.86 | 6.44% |
West Pharmaceutical Services Inc | Buy | $27.8B | 238.38% | 48.1 | 20.12% |
Alcon Ag | Buy | $39.5B | 42.78% | 40.62 | 10.3% |
Vanguard Group Inc
BlackRock Inc
Kayne Anderson Rudnick Investment Management LLC
Politan Capital Management LP
Dimensional Fund Advisors, Inc.
NORGES BANK
In the quarter ending June,2021. Azenta Inc has declared dividend of $0.1
Read Moreazenta (nasdaq: azta) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. azenta provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. azenta is headquartered in chelmsford, ma, with operations in north america, europe and asia. for more information, please visit www.azenta.com.
Organization | Azenta Inc |
Employees | 3500 |
CEO | Dr. Stephen S. Schwartz |
Industry | Technology |